Dashboard
Kymera Therapeutics, Inc.
KYMRNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 2Trial readoutClinicalTrials.gov
Kymera completes Phase 1 first-in-human study of KT-579 in healthy adults (NCT07412288).
- Oct 30Trial initiationClinicalTrials.gov
Kymera initiates Phase 1 trial NCT07823205 evaluating different oral formulations of KT-621; status recruiting.
- Oct 29Financial resultsSEC
Kymera Therapeutics filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
- Oct 7Trial initiationClinicalTrials.gov
Kymera starts Phase 2 long-term extension study of KT-621 in prior asthma trial participants (NCT07677059, recruiting)
- Oct 6Trial initiationClinicalTrials.gov
Kymera updates Phase 2 trial NCT07217015 of KT-621 in moderate to severe atopic dermatitis to ACTIVE_NOT_RECRUITING status.
- Oct 6Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial of KT-621 in moderate to severe eosinophilic asthma (NCT07323654, recruiting).
- Oct 1Ownership changeSEC
SEC Form 4 insider transaction filing.
- Sep 16Trial initiationClinicalTrials.gov
Phase 1 trial NCT07823205 initiated to evaluate oral formulations of KT-621; recruiting.
- Sep 4Ownership changeSEC
SEC Form 4 insider transaction filing.
- Aug 17Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial (NCT07323654) of KT-621 in moderate to severe eosinophilic asthma; recruiting status as of 2026-08-17.
- Aug 5Financial resultsSEC
Kymera Therapeutics files 8-K (items 2.02, 9.01) disclosing financial results.
- Jul 27LeadershipSEC
8-K filed with items 5.02, 7.01, 9.01 covering officer or director changes and related exhibits.
- Jul 27Ownership changeSEC
SEC Form 4 filed reporting insider transaction in KYMR shares.
- Jul 7Ownership changeSEC
Form 4 filing reporting change in beneficial ownership.
- Jul 2Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jul 2Ownership changeSEC
SEC Form 4 insider ownership filing.
- Jul 2Ownership changeSEC
SEC Form 4 insider ownership filing.
- Jun 30Ownership changeSEC
SEC Form 4 insider transaction filing
- Jun 30Ownership changeSEC
SEC Form 4 insider transaction filing.
- Jun 30Trial initiationClinicalTrials.gov
Phase 2 trial (NCT07217015) of KT-621 in moderate to severe atopic dermatitis updated to active, not recruiting.
Not financial advice — research and opinion only. Disclosures